Should Genotype Guide Thromboprophylaxis in Pregnant Women With Antithrombin Deficiency? – RPTH Journal
RPTH Journal shared a post on LinkedIn about a recent article by Björn Diemer et al., adding:
“Antithrombin deficiency and obstetric complications: should genotype guide thromboprophylaxis decisions for ?
Hereditary antithrombin (AT) deficiency increases the risk of both VTE and obstetric complications during pregnancy. But not all subtypes carry the same risk; and whether genotyping can help personalise treatment decisions has remained unclear.
A new retrospective cohort study in RPTH Journal followed 43 women with AT deficiency across 106 pregnancies at Karolinska Institutet University Hospital (1990–2022):
- Women were stratified into low-risk (type IIHBS; n=26) and high-risk (types I, IIPE, IIRS; n=17) groups based on genotype
- In the low-risk group, 24% of untreated women developed pre-eclampsia vs none among treated women (P = .005)
- Intrauterine fetal death occurred in 20% of untreated women in the low-risk group vs none among treated women (P = .014)
No statistically significant difference in VTE incidence between high-risk and low-risk groups
Women with the ‘low-risk’ IIHBS subtype may still face significant obstetric complications when untreated. Genotyping alone may not be sufficient to withhold thromboprophylaxis, and a broader view of pregnancy risk beyond VTE is essential in this population.
This is a small retrospective single-centre study spanning over 30 years, with inherent limitations in consistency of management and data completeness. Larger prospective studies are needed to confirm these findings.”
Title: Risk stratification according to genotype and effect of thromboprophylaxis on obstetric outcomes in women with antithrombin deficiency
Authors: Björn Diemer, Nina Iversen, Lana Othman, Eva-Lotta Hempel, Roza Chaireti, Katarina Bremme
Other articles featuring RPTH Journal on Hemostasis Today.
-
Nov 5, 2026, 00:36Looking Forward to the Upcoming ERIN Webinar – EAHAD
-
Nov 4, 2026, 23:49Jyotsnaa Rao: Contributing to Advances in Transfusion Medicine Through TPE in Solid Organ Transplantation
-
Nov 4, 2026, 23:28Flávio Augusto Naoum: Discussing Digital Morphology and the Burden of Anemia in Myelofibrosis at HEMO 2026
-
Nov 4, 2026, 22:53Rana Al-Hrout: Approach to Thrombocytopenia – A Practical Diagnostic Roadmap
-
Nov 4, 2026, 22:38Caitlin Raymond: What the Longevity Trial Actually Shows About Plasma Exchange and Biological Aging
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A